NASDAQ:ATRI - Atrion Stock Price, News, Headlines & Rumors

Sign in or create an account to add this stock to your watchlist.
$657.85 -11.15 (-1.67 %)
(As of 08/16/2018 04:00 PM ET)
Previous Close$669.00
Today's Range$655.40 - $679.50
52-Week Range$516.85 - $694.25
Volume9,400 shs
Average Volume8,318 shs
Market Capitalization$1.18 billion
P/E Ratio34.99
Dividend Yield0.73%
Beta0.64
Atrion logoAtrion Corporation develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications worldwide. Its fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments. The company's cardiovascular products comprise MPS2 myocardial protection system that delivers fluids and medications, and mixes critical drugs, as well as controls temperature, pressure, and other variables; cardiac surgery vacuum relief valves; silicone vessel loops for retracting and occluding vessels; and inflation devices for balloon catheter dilation, stent deployment, and fluid dispensing, as well as products that are used in heart bypass surgery. Its ophthalmic products include specialized medical devices that disinfect contact lenses; and a line of balloon catheters, which are used for the treatment of nasolacrimal duct obstruction in children and adults. The company also manufactures instrumentation and associated disposables that measures the activated clotting time of blood; and a line of products designed for safe needle and scalpel blade containment. In addition, it manufactures inflation systems and valves used in marine and aviation safety products; components used in inflatable survival products and structures; one-way and two-way pressure relief valves that protect sensitive electronics; and other products during transport in other medical and non-medical applications. The company sells its products to physicians, hospitals, clinics, and other treatment centers, as well as other equipment manufacturers through direct sales personnel, independent sales representatives, and distributors. Atrion Corporation was founded in 1944 and is headquartered in Allen, Texas.

Receive ATRI News and Ratings via Email

Sign-up to receive the latest news and ratings for ATRI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
SymbolNASDAQ:ATRI
CUSIP04990410
Phone972-390-9800

Debt

Debt-to-Equity RatioN/A
Current Ratio11.03
Quick Ratio7.88

Price-To-Earnings

Trailing P/E Ratio34.99
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$146.60 million
Price / Sales8.30
Cash Flow$23.9741 per share
Price / Cash27.44
Book Value$99.57 per share
Price / Book6.61

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$36.59 million
Net Margins22.57%
Return on Equity17.99%
Return on Assets16.16%

Miscellaneous

Employees528
Outstanding Shares1,850,000
Market Cap$1.18 billion

Atrion (NASDAQ:ATRI) Frequently Asked Questions

What is Atrion's stock symbol?

Atrion trades on the NASDAQ under the ticker symbol "ATRI."

How often does Atrion pay dividends? What is the dividend yield for Atrion?

Atrion declared a quarterly dividend on Tuesday, August 14th. Investors of record on Friday, September 14th will be paid a dividend of $1.35 per share on Friday, September 28th. This represents a $5.40 annualized dividend and a yield of 0.82%. The ex-dividend date of this dividend is Thursday, September 13th. This is an increase from Atrion's previous quarterly dividend of $1.20. View Atrion's Dividend History.

How were Atrion's earnings last quarter?

Atrion Co. (NASDAQ:ATRI) announced its quarterly earnings results on Tuesday, February, 27th. The medical instruments supplier reported $4.66 earnings per share for the quarter. The medical instruments supplier earned $34.02 million during the quarter. Atrion had a net margin of 22.57% and a return on equity of 17.99%. View Atrion's Earnings History.

When is Atrion's next earnings date?

Atrion is scheduled to release their next quarterly earnings announcement on Wednesday, November, 14th 2018. View Earnings Estimates for Atrion.

Who are some of Atrion's key competitors?

Who are Atrion's key executives?

Atrion's management team includes the folowing people:
  • Mr. Emile A. Battat, Exec. Chairman (Age 80)
  • Mr. David A. Battat, Pres & CEO (Age 48)
  • Mr. Jeffery Strickland, VP, CFO, Sec. & Treasurer (Age 59)

Has Atrion been receiving favorable news coverage?

Press coverage about ATRI stock has trended positive on Thursday, Accern reports. The research firm identifies positive and negative news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Atrion earned a media and rumor sentiment score of 0.32 on Accern's scale. They also assigned media coverage about the medical instruments supplier an impact score of 47.40 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next several days. View Recent Headlines for Atrion.

Who are Atrion's major shareholders?

Atrion's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.38%), Renaissance Technologies LLC (3.76%), Royce & Associates LP (2.12%), FMR LLC (0.82%), BTIM Corp. (0.78%) and Pennsylvania Trust Co (0.58%). Company insiders that own Atrion stock include Emile A Battat, Hugh J Morgan Jr and Jeffery Strickland. View Institutional Ownership Trends for Atrion.

Which institutional investors are selling Atrion stock?

ATRI stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Millennium Management LLC, American Century Companies Inc., Eqis Capital Management Inc., Livingston Group Asset Management CO operating as Southport Capital Management, Zebra Capital Management LLC, Bank of America Corp DE and California Public Employees Retirement System. View Insider Buying and Selling for Atrion.

Which institutional investors are buying Atrion stock?

ATRI stock was bought by a variety of institutional investors in the last quarter, including BTIM Corp., Renaissance Technologies LLC, BlackRock Inc., Citadel Advisors LLC, Denali Advisors LLC, BlueMountain Capital Management LLC, First Trust Advisors LP and Spark Investment Management LLC. View Insider Buying and Selling for Atrion.

How do I buy shares of Atrion?

Shares of ATRI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Atrion's stock price today?

One share of ATRI stock can currently be purchased for approximately $657.85.

How big of a company is Atrion?

Atrion has a market capitalization of $1.18 billion and generates $146.60 million in revenue each year. Atrion employs 528 workers across the globe.

How can I contact Atrion?

Atrion's mailing address is ONE ALLENTOWN PARKWAY, ALLEN TX, 75002. The medical instruments supplier can be reached via phone at 972-390-9800 or via email at [email protected]


MarketBeat Community Rating for Atrion (NASDAQ ATRI)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  65 (Vote Outperform)
Underperform Votes:  74 (Vote Underperform)
Total Votes:  139
MarketBeat's community ratings are surveys of what our community members think about Atrion and other stocks. Vote "Outperform" if you believe ATRI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATRI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.